TY -的T1神经丝光测试结果变化明显不同试验平台和分析试剂(p1.9 - 066) JF -神经学乔-神经学六世- 92 - 15补充SP - p1.9 - 066 AU - Florian Deisenhammer盟玛蒂娜Podlesnic盟Jens Kuhle A首页U -大卫Leppert盟Zuzanna旧事的非盟-朱利安Deisenhammer盟凯瑟琳Schanda盟——Rainer艾莉盟马库斯Reindl Y1 - 2019/04/09 UR - //www.ez-admanager.com/content/92/15_supplement/p1.9 - 066. -文摘N2 -目的:比较不同神经丝灯(NfL)链蛋白质制剂在不同试验平台。背景:橄榄球联盟被认为是neuro-axonal损伤的生物标志物在神经系统疾病和一个可能的替代标记女士然而,大多数研究都是基于一个化验和彻底的比较测量技术是失踪。设计/方法:我们使用以下NfL准备:从乌曼商用牛NfL诊断(Uman-NfL),商用重组人类从Origene NfL (Origene-NfL)和人类NfL表达大肠杆菌(hurec-NfL)。NfL ELISA检测了乌曼(诊断),免疫印迹,液体chromatography-tandem质谱(质/ MS)和单分子阵列(SIMOA)平台。NfL在适当的缓冲和稀释Origene-PC也上升到2在不同浓度血清(200、20、2和0.2 ng / mL)在SIMOA和测试。同样,血清样品浓度的30,3.3,0.37,和0.04 ng / mL ELISA检测。结果:在质/女士Origene NfL可以检测到但不Uman-NfL (hurec-NfL没有完成)。在ELISA Uman-NfL hurec-NfL返回预期的浓度,但Origene-NfL没有信号。在西方墨点法有NfL-specific乐队为Uman-NfL Origene-NfL和hurec-NfL但不。飙升的平均结果样本在SIMOA 10, 1.5, 0.15,和0.03 ng / mL,即8-20褶皱低于预期。ELISA结果飙升样本3.02,0.4,0.1,0.5和0.08 ng / mL,即比预期少-10倍。结论:有一个显著的区别之间的NfL检测各种试验平台。转译后的修改,如磷酸化、糖基化、硝化、氧化和ubiquitylation也许可以解释一些观察但不ELISA的事实是无法检测到纯Origine-NfL而发现如果上升到血清。 This might hint to strong matrix effects or a specificity issue with the assay reagents. Further studies for cross-platform NfL assay validation are needed.Disclosure: Dr. Deisenhammer has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen, Celgene, Genzyme, Merck, Novartis, and Roche. Dr. Deisenhammer has received research support from by Biogen and Genzyme-Sanofi. Dr. Podlesnic has nothing to disclose. Dr. Kuhle’s institution has received compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen, Novartis Pharmaceuticals, Protagen AG, Roche, Teva, Sanofi Genzyme, Swiss MS Society, and Merck Serono,. Dr. Kuhle has received research support from ECTRIMS Research Fellowship Programme, Bayer AG, Biogen, Sanofi Genzyme, Merck, Novartis Pharmaceuticals, Roche, Swiss MS Society, Swiss National Research Foundation, and University of Basel. Dr. Leppert has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Novartis. Dr. Michalak has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Novartis Pharma AG, Basel, Switzerland. Dr. Deisenhammer has nothing to disclose. Dr. Schanda has nothing to disclose. Dr. Ehling has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen. Dr. Reindl has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Chugai.. Dr. Reindl has received research support from The Neurological Research Laboratory (Markus Reindl, Medical University of Innsbruck and Tirol Kliniken), Euroimmu. ER -